Searched for
SURAJIT PAL
Maoist top gun Ranjit Pal, wife surrender in KolkataRanjit has more than 50 cases of abduction, murder and extortion in Purulia, Bankura and West Midnapore districts.- Glenmark rally totally unjustifiable and illogical: Prabhudas Lilladher‘I really do not think there will be any kind of big benefit out of Fabiflu’
- Why are pharma stocks rallying? Surajit Pal explains‘The US market provides good revenue in dollars which is a bonus’
- Lupin, Cipla, Aurobindo dogged by USFDA hurdles: Surajit Pal, Prabhudas LilladherThe turnaround time will be different for different companies depending on complexity of issues.
- Pharma cos staring at some margin pressure: Surajit Pal, Prabhudas Lilladher"Non-sterile plants getting stuck for such a long time are really surprising."
- Do not expect any drastic improvement in US generic market: Surajit Pal, Prabhudas LilladherInstead of 10-12%, generic pharma price fall may stabilise at 8-10%, says Pal.
- What $900-mn buy means for Aurobindo Pharma: Surajit Pal, Prabhudas Lilladher“Aurobindo Pharma is looking at extending sales & reach with US acquisition.”
- Generis buy should be good for Aurobindo Pharma: Surajit Pal, Prabhudas LiladherMy problem with a company like Granules is that I really cannot bet on a company which is betting highly on a highly commoditised product, ...
- Sun Pharma Q1 profit soars three fold to 2,034 croreThe company, which had recorded net profit of Rs 555.9 crore in the year-ago quarter, pointed out that last year its net profit was impacte...
- Sun Pharma Q1 net up three fold at rs 2,033.71 croreThe company mainly benefited from the exclusivity opportunity for anti-cancer drug imatinib in the US.
- Sun Pharma announces buyback plan at Rs 900 per shareThe buyback price comes at a 16 per cent premium over Rs 752, the closing price of Sun Pharma on Thursday at BSE.
- US market no longer a low hanging fruit, pharma cos go back to lab: Surajit Pal, Research Analyst, Prabhudas LilladherThe only way you can increase your US sales is by that acquisition in generics and keep on investing in R&D to get a product which will boo...
- Need to see how serious were the US FDA observations against Lupin Goa plant: Surajit Pal, Prabhudas LilladherThere will be many companies which will face degrowth in US revenues.in FY17
- Sun Pharma gains 2 per cent as company bids to acquire InSite VisionShares of Sun Pharmacauticals gained about 3% on reports that the company has bid to acquire US-based eye care company InSite Vision Inc.
- Sun Pharma's acquisition of Ranbaxy will be synergistic: Surajit Pal, Prabhudas LilladherFrom the very beginning I did not understand much of logic for Sun Pharma’s acquisition of Ranbaxy, because that acquisition was not that g...
- Ranbaxy to suffer operating losses post USFDA ban: Surajit Pal, Prabhudas Lilladher"For the Ohm Labs to manufacture formulations, around 70% of the supplies came from the Toansa API plant. So that business would be impacte...
- Ranbaxy Q1 numbers positively surprised everybody: Surajit Pal, Elara CapitalThe market had reacted yesterday not to the top line growth of Ranbaxy. This is because that is very much in line with the expectations.
- Ranbaxy gains over 5% in trade; drug release on trackShares of Ranbaxy climbed over 5 per cent in trade on Thursday on reports that the company will release a generic version Lipitor in the US...
- Elara maintains sell on Sun Pharma; price target at Rs 410Elara Capital has maintained a sell rating on Sun Pharmaceuticals with a price target of Rs410 citing expensive valuations and hazy busines...
- Insulin will be a major trigger for Biocon: Elara CapitalSurajit Pal, Analyst, Elara Capital in an interview with ET Now gives his perspective on pharma stocks.
Load More
